Related Experiment Video
Updated: Jan 27, 2026

Building a Better Mosquito: Identifying the Genes Enabling Malaria and Dengue Fever Resistance in A. gambiae and A. aegypti Mosquitoes
Published on: July 4, 2007
The Role of Familial Mediterranean Fever Gene Mutation in Treatment of Infantile Colitis With Resistant Perianal
Maşallah Baran1, Yeliz Çağan Appak2, Pınar Garipcin3
1Department of Pediatric Gastroenterology, Hepatology and Nutrition, İzmir Katip Çelebi University School of Medicine, İzmir, Turkey.
Abstract:
Symptoms of infantile inflammatory bowel disease (I-IBD) can be life-threatening and associated with poor prognosis. The presence of Mediterranean fever (MEFV) gene mutations play an important role in treatment of I-IBD. In this article, we describe a case of I-IBD with a resistant fistula, in which remission occurred following colchicine therapy. The patient was a six-month-girl with complaints of bloody diarrhea and a perianal abscess of three months duration. Laboratory tests revealed elevated inflammatory parameters, hypoalbuminemia, and anemia. Results of repeated viral, bacterial and parasitic analyses were negative. Endoscopic and histopathological examinations confirmed a diagnosis of I-IBD. Although diarrhea episodes decreased following intensive conventional treatment with immunosuppressive therapy and anti-tumor necrosis factor, the perianal abscess and fistula did not resolve. Molecular genetic analysis to identify causes of infantile disease revealed the MEFV gene mutation. Thus, colchicine was added to the treatment regimen. Following treatment with colchicine, defecation returned to normal, and the fistula resolved. The MEFV gene mutation should be investigated in children with infantile colitis and resistant fistulas, particularly in Mediterranean countries. In patients with infantile colitis who have the MEFV gene mutation, colchicine treatment may be an alternative to intensive immunosuppressive therapy.
Insights
Infantile inflammatory bowel disease (I-IBD) can be severe. Colchicine therapy effectively treated a resistant fistula in an infant with an MEFV gene mutation, suggesting a new treatment approach.
Area of Science:
- Pediatrics
- Gastroenterology
- Genetics
Background:
- Infantile inflammatory bowel disease (I-IBD) presents with severe symptoms and poor prognosis.
- Mediterranean fever (MEFV) gene mutations are implicated in I-IBD pathogenesis and treatment.
- Conventional therapies often fail to resolve complications like fistulas in I-IBD.
Observation:
- A six-month-old infant presented with persistent bloody diarrhea and a perianal abscess.
- Standard treatments including immunosuppressants and anti-tumor necrosis factor were ineffective.
- Genetic analysis revealed a mutation in the MEFV gene.
Findings:
- Colchicine therapy led to complete remission of symptoms, including resolution of the perianal fistula.
- The patient experienced normalization of bowel function after colchicine treatment.
- MEFV gene mutation was identified as a key factor in treatment response.
Implications:
- Investigating MEFV gene mutations is crucial for children with refractory I-IBD and fistulas, especially in Mediterranean populations.
- Colchicine offers a potential alternative to intensive immunosuppressive therapy for I-IBD patients with MEFV mutations.
- This case highlights the importance of genetic screening in diagnosing and managing complex pediatric inflammatory bowel disease.
Related Concept Videos
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Gene Families
Protein Families
Mutation, Gene Flow, and Genetic Drift
Drugs for Treatment of Ulcerative Colitis in IBD
Treatment Resistant Cancers

